Pfizer Inc. $PFE Shares Acquired by Centric Wealth Management

Key Points

• Centric Wealth Management increased its holdings in Pfizer Inc. by 23.4%, acquiring an additional 20,164 shares, bringing its total to 106,161 shares worth approximately $2.69 million.
• Pfizer recently declared a quarterly dividend of $0.43, reflecting an annual yield of 7.0% and a payout ratio of 91.49%.
• The company's stock has a market capitalization of $140.65 billion and has recently seen analysts set price targets ranging from $25.00 to $33.00, with a consensus target price of $28.12.

Centric Wealth Management boosted its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 23.4% in the first quarter, according to the company in its most recent filing with the SEC. The firm owned 106,161 shares of the biopharmaceutical company's stock after acquiring an additional 20,164 shares during the quarter. Centric Wealth Management's holdings in Pfizer were worth $2,690,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in PFE. Brighton Jones LLC lifted its position in Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock worth $17,677,000 after acquiring an additional 618,117 shares during the period. Revolve Wealth Partners LLC lifted its holdings in shares of Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock valued at $498,000 after buying an additional 2,087 shares during the period. Triumph Capital Management lifted its holdings in shares of Pfizer by 20.0% in the 4th quarter. Triumph Capital Management now owns 10,283 shares of the biopharmaceutical company's stock valued at $273,000 after buying an additional 1,717 shares during the period. Freestone Grove Partners LP acquired a new position in shares of Pfizer in the 4th quarter valued at about $481,000. Finally, Eagle Strategies LLC lifted its holdings in shares of Pfizer by 30.5% in the 4th quarter. Eagle Strategies LLC now owns 12,212 shares of the biopharmaceutical company's stock valued at $324,000 after buying an additional 2,852 shares during the period. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Price Performance

NYSE:PFE traded up $0.14 during trading hours on Friday, hitting $24.74. 37,002,549 shares of the stock were exchanged, compared to its average volume of 42,996,172. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $30.43. The firm's fifty day moving average price is $24.79 and its 200 day moving average price is $24.37. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The company has a market cap of $140.65 billion, a P/E ratio of 13.16, a P/E/G ratio of 0.88 and a beta of 0.55.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. During the same period in the previous year, the business earned $0.60 EPS. Pfizer's quarterly revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.0%. The ex-dividend date is Friday, July 25th. Pfizer's payout ratio is 91.49%.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Citigroup boosted their price objective on Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. HSBC decreased their price objective on Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a report on Monday, May 19th. Jefferies Financial Group lifted their price target on Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a research note on Wednesday, May 21st. Berenberg Bank cut their price target on Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a research note on Thursday, May 29th. Finally, Bank of America lifted their price target on Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a research note on Wednesday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Pfizer has a consensus rating of "Hold" and a consensus target price of $28.12.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.